Sustained Effectiveness of a Fixed-Dose Combination of Artesunate and Amodiaquine in 480 Patients with Uncomplicated Plasmodium falciparum Malaria in Côte d’Ivoire

Table 4

Overview of adverse events.

	Period 1	Period 2	value
	= 290	= 290
Any adverse event	145 (50.0%)	114 (39.3%)	0.010
Potentially ASAQ-related adverse events	14 (4.8%)	5 (1.7%)	<0.001
Serious adverse event	3 (1.0%)	2 (0.7%)	1.000
Severe adverse events	8 (2.8%)	8 (2.8%)	1.000
Deaths	None	None	—
Adverse events leading to treatment discontinuation	None	None	—

Data are presented as the number of patients presenting at least one adverse event.